This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
BEAMNegative Net Change FOLDNegative Net Change ANIPNegative Net Change MDGLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
by Zacks Equity Research
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
NVONegative Net Change LLYPositive Net Change BEAMNegative Net Change FOLDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Markets Stay Lower on Valuation Questions: AI, etc.
by Mark Vickery
We've entered the rapid-pace phase of Q3 earnings season, where results tend to come in more blended than they do for the earlier-reporting sectors.
AMDNegative Net Change AMGNNegative Net Change SMCINegative Net Change PINSNegative Net Change RIVNNegative Net Change
biotechnology earnings semiconductor tech-stocks
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
by Zacks Equity Research
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
BEAMNegative Net Change FOLDNegative Net Change ZTSNegative Net Change ANIPNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
BEAMNegative Net Change NBIXNegative Net Change FOLDNegative Net Change XENEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
by Zacks Equity Research
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
GSKPositive Net Change ALKSNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
ANIPNegative Net Change CRSPNegative Net Change IMCRPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris to Report Q3 Earnings: Is a Beat in the Cards for the Stock?
by Zacks Equity Research
VTRS is set to report Q3 results, with brand strength offsetting generics pressure and a model hinting at an earnings beat.
NKTRNegative Net Change ANIPNegative Net Change ZYMENegative Net Change VTRSNegative Net Change
biotechnology earnings medical pharmaceuticals
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
ZYME, NKTR, ANIP, and PCRX are poised for potential Q3 earnings surprises as the biotech sector shows strong momentum.
NKTRNegative Net Change PCRXNegative Net Change ANIPNegative Net Change ZYMENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
by Ekta Bagri
Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.
AZNPositive Net Change JNJPositive Net Change BDTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
BEAMNegative Net Change FOLDNegative Net Change ANIPNegative Net Change APLSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
by Zacks Equity Research
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
ALNYPositive Net Change RHHBYPositive Net Change BEAMNegative Net Change FOLDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
by Zacks Equity Research
Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.
GSKPositive Net Change ALKSNegative Net Change GILDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Prescription for Beats: 3 Healthcare Stocks Set to Outperform in Q3
by Kaibalya Pravo Dey
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
HUMNegative Net Change CORPositive Net Change GMEDNegative Net Change
biotechnology earnings insurance medical medical-devices pharmaceuticals
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
PFENegative Net Change TBPHPositive Net Change CRMDNegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
by Zacks Equity Research
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
BMYNegative Net Change PFENegative Net Change ALKSNegative Net Change BNTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
ALNYPositive Net Change VRTXPositive Net Change ZTSNegative Net Change EXASNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
by Zacks Equity Research
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.
ALKSNegative Net Change ANIPNegative Net Change AVDLPositive Net Change HOWLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
by Zacks Equity Research
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology earnings medical pharmaceuticals
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
NVSNegative Net Change LLYPositive Net Change INCYNegative Net Change ANIPNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
by Ahan Chakraborty
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs hospitals medical pharmaceuticals
EastGroup Properties (EGP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
EGPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
RDYPositive Net Change MRKPositive Net Change AMGNNegative Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals